How do molecular and clinical factors guide personalized selection of HSRT dose fractionation regimens with bevacizumab in recurrent high-grade gliomas?  

Multivariate analysis identified HSRT dose fractionation, tumor grade, IDH mutation, and 1p/19q codeletion as significant predictors of PFS- do these findings support moving toward a biomarker-driven stratification approach in future trials?

This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Clinical Trials Session Presentation "Efficacy of Hypofractionated Stereotactic Radiotherapy with Different Dose Fractionation Regimens Combined with Concurrent Bevacizumab in Recurrent High-Grade Gliomas: A Randomized Controlled Trial" by Dr. Feng Liu.